Physician profile
Amelia M Jernigan
NPI 1275777682
$84,678.53
in general payments reported to CMS, 2019-2025
39 companies · $23K in 2025
The $23K reported for 2025 was more than what 94% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $887 · 2020: $29.81 · 2021: $18K · 2022: $7,672 · 2023: $22K · 2024: $13K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Consulting Fee: $11K · Travel and Lodging: $6,700 · Food and Beverage: $4,589 · Honoraria: $350 · Education: $30.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,340.00 |
| Consulting Fee | $10,787.50 |
| Travel and Lodging | $6,699.97 |
| Food and Beverage | $4,589.23 |
| Honoraria | $350.00 |
| Education | $30.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $67,553.64 | 2019-2025 | Lynparza |
| Merck Sharp & Dohme LLC | $11,855.06 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Glaxosmithkline, LLC. | $620.17 | 2023-2025 | Jemperli, Zejula |
| Eisai INC. | $569.74 | 2021-2025 | |
| Meditrina | $363.43 | 2025 | |
| Intuitive Surgical, INC. | $320.27 | 2019-2022 | |
| Daiichi Sankyo INC. | $318.00 | 2024 | Enhertu |
| Abbvie INC. | $277.74 | 2020-2025 | |
| Medtronic, INC. | $260.39 | 2024-2025 | Signia |
| Baxter Healthcare | $179.69 | 2021 | |
| Janssen Biotech, INC. | $178.68 | 2023 | Erleada |
| Pacira Pharmaceuticals Incorporated | $163.90 | 2022 | |
| Immunogen, INC. | $161.91 | 2023 | Elahere |
| Biom'Up France Sas | $159.06 | 2021 | |
| Tesaro, INC. | $153.62 | 2019 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amelia Jernigan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.